Collaboration Agreements - Narrative (Details) - USD ($)	Sep. 30, 2025	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract liabilities	$ 0	$ 0
Accounts receivable, net	171,254,000	142,077,000
Biogen Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable, net	19,900,000	$ 0
Shionogi \| License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract liabilities	90,000,000
Revenue, remaining performance obligation, variable consideration amount	470,000,000
Shionogi \| License \| Achievement Of Specified Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	55,000,000
Shionogi \| License \| Achievement Of Specified Commercialization Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	30,000,000
Shionogi \| License \| Achievement Of Specified Net Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	$ 385,000,000

SUPERNUS PHARMACEUTICALS, INC. 10-Q